nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

18.08.2023 | Review

Progress of immunotherapies in gestational trophoblastic neoplasms

verfasst von: Tong Wang, Wenxiu Guo, Xiaochen Ren, Fangfang Lang, Ying Ma, Chunping Qiu, Jie Jiang

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 16/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Different from other malignant gynecologic tumors, gestational trophoblastic neoplasms (GTNs) exhibit an exceptionally high cure rate primarily through chemotherapeutic interventions. However, there exists a small subset of refractory GTNs that do not respond to conventional chemotherapies. In such cases, the emergence of immunotherapies has demonstrated significant benefits in managing various challenging GTNs.

Purpose

This article aims to provide a comprehensive and systematic review of the immune microenvironment and immunotherapeutic approaches for GTNs. The purpose is to identify potential biomarkers that could enhance disease management and summarize the available immunotherapies for ease of reference.

Methods

We reviewed the relevant literatures toward immunotherapies of GTNs from PubMed.

Conclusion

Current immunotherapeutic strategies for GTNs mainly revolve around immune checkpoint inhibitors (ICIs) targeting programmed death receptor 1 (PD-1) and programmed cell death ligand 1 (PD-L1). Prominent examples include avelumab, pembrolizumab, and camrelizumab. However, existing researches into the underlying mechanisms are still limited.

Abu-Rustum NR, Yashar CM, Bean S et al (2019) Gestational trophoblastic neoplasia, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 17(11):1374–1391PubMedCrossRef

Anantharaju AA, Pallavi VR, Bafna UD et al (2019) Role of salvage therapy in chemo resistant or recurrent high-risk gestational trophoblastic neoplasm. Int J Gynecol Cancer 29(3):547–553PubMedCrossRef

Artenie A, Stone J, Fraser H et al (2023) Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis. Lancet Gastroenterol Hepatol 8(6):533–552PubMedCrossRef

Banach P, Dereziński P, Matysiak J et al (2018) Serum angiogenesis profile in gestational trophoblastic neoplasm using multiplex immunoassay. Life Sci 211:25–30PubMedCrossRef

Barsoum IB, Smallwood CA, Siemens DR et al (2014) A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res 74(3):665–674PubMedCrossRef

Berkowitz RS, Goldstein DP (2009) Clinical practice. Molar Pregnancy. N Engl J Med 360(16):1639–1645PubMedCrossRef

Bolze PA, Patrier S, Massardier J et al (2017) PD-L1 expression in premalignant and malignant trophoblasts from gestational trophoblastic diseases is ubiquitous and independent of clinical outcomes. Int J Gynecol Cancer 27(3):554–561PubMedCrossRef

Borella F, Cosma S, Ferraioli D et al (2022) From uterus to brain: an update on epidemiology, clinical features, and treatment of brain metastases from gestational trophoblastic neoplasia. Front Oncol 12:859071PubMedPubMedCentralCrossRef

Braga A, Elias KM, Horowitz NS et al (2021) Treatment of high-risk gestational trophoblastic neoplasia and chemoresistance/relapsed disease. Best Pract Res Clin Obstet Gynaecol 74:81–96PubMedCrossRef

Carosella ED, Rouas-Freiss N, Tronik-Le Roux D et al (2015) HLA-G: an immune checkpoint molecule. Adv Immunol 127:33–144PubMedCrossRef

Cheng H, Zong L, Kong Y et al (2021) Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial. Lancet Oncol 22(11):1609–1617PubMedCrossRef

Choi MC, Oh J, Lee C (2019) Effective anti-programmed cell death 1 treatment for chemoresistant gestational trophoblastic neoplasia. Eur J Cancer 121:94–97PubMedCrossRef

Clair KH, Gallegos N, Bristow RE (2020) Successful treatment of metastatic refractory gestational choriocarcinoma with pembrolizumab: a case for immune checkpoint salvage therapy in trophoblastic tumors. Gynecol Oncol Rep 34:100625PubMedPubMedCentralCrossRef

Fanoni D, Tavecchio S, Recalcati S et al (2011) New monoclonal antibodies against B-cell antigens: possible new strategies for diagnosis of primary cutaneous B-cell lymphomas. Immunol Lett 134(2):157–160PubMedCrossRef

Frijstein MM, Lok CAR, Short D et al (2019) The results of treatment with high-dose chemotherapy and peripheral blood stem cell support for gestational trophoblastic neoplasia. Eur J Cancer 109:162–171PubMedCrossRef

Ghorani E, Kaur B, Fisher RA et al (2017) Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia. Lancet 390(10110):2343–2345PubMedCrossRef

Habicht A, Dada S, Jurewicz M et al (2007) A link between PDL1 and T regulatory cells in fetomaternal tolerance. J Immunol 179(8):5211–5219PubMedCrossRef

Hancock BW, Tidy J (2021) Placental site trophoblastic tumour and epithelioid trophoblastic tumour. Best Pract Res 74:131–148CrossRef

Hoeijmakers YM, Gorris MAJ, Sweep FCGJ et al (2021) Immune cell composition in the endometrium of patients with a complete molar pregnancy: effects on outcome. Gynecol Oncol 160(2):450–456PubMedCrossRef

Horowitz NS, Goldstein DP, Berkowitz RS (2017) Placental site trophoblastic tumors and epithelioid trophoblastic tumors: biology, natural history, and treatment modalities. Gynecol Oncol 144(1):208–214PubMedCrossRef

Huang M, Pinto A, Castillo RP et al (2017) Complete serologic response to pembrolizumab in a woman with chemoresistant metastatic choriocarcinoma. J Clin Oncol 35(27):3172–3174PubMedCrossRef

Humeau J, Sauvat A, Cerrato G et al (2020) Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress. EMBO Mol Med 12(5):e11622PubMedPubMedCentralCrossRef

Ikoma Y, Nomura S, Ito T et al (2003) Interleukin-1beta stimulates placental leucine aminopeptidase/oxytocinase expression in BeWo choriocarcinoma cells. Mol Hum Reprod 9(2):103–110PubMedCrossRef

Inaguma S, Wang Z, Lasota J et al (2016) Comprehensive immunohistochemical study of programmed cell death ligand 1 (PD-L1): analysis in 5536 cases revealed consistent expression in trophoblastic tumors. Am J Surg Pathol 40(8):1133–1142PubMedPubMedCentralCrossRef

Ishii M, Hayakawa S, Suzuki MK et al (2000) Expression of functional chemokine receptors of human placental cells. Am J Reprod Immunol 44(6):365–373PubMedCrossRef

Jørgensen N, Persson G, Hviid TVF (2019) The tolerogenic function of regulatory T cells in pregnancy and cancer. Front Immunol 10:911PubMedPubMedCentralCrossRef

Kaur B (2021) Pathology of gestational trophoblastic disease (GTD). Best Pract Res Clin Obstet Gynaecol 74:3–28PubMedCrossRef

Knoeller S, Lim E, Aleta L et al (2003) Distribution of immunocompetent cells in decidua of controlled and uncontrolled (choriocarcinoma/hydatidiform mole) trophoblast invasion. Am J Reprod Immunol 50(1):41–47PubMedCrossRef

Lala PK, Nandi P (2016) Mechanisms of trophoblast migration, endometrial angiogenesis in preeclampsia: the role of decorin. Cell Adh Migr 10(1–2):111–125PubMedPubMedCentralCrossRef

Lala PK, Nandi P, Hadi A et al (2021) A crossroad between placental and tumor biology: What have we learnt? Placenta 116:12–30PubMedCrossRef

Lan R, Yang Y, Song J et al (2021) Fas regulates the apoptosis and migration of trophoblast cells by targeting NF-κB. Exp Ther Med 22(4):1055PubMedPubMedCentralCrossRef

Landskron G, De la Fuente M, Thuwajit P et al (2014) Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res 2014:149185PubMedPubMedCentralCrossRef

Lappas M, Yee K, Permezel M et al (2006) Lipopolysaccharide and TNF-alpha activate the nuclear factor kappa B pathway in the human placental JEG-3 cells. Placenta 27(6–7):568–575PubMedCrossRef

Lu B, Teng X, Fu G et al (2019) Analysis of PD-L1 expression in trophoblastic tissues and tumors. Hum Pathol 84:202–212PubMedCrossRef

Lurain JR (2010) Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol 203(6):531–539PubMedCrossRef

Lurain JR, Nejad B (2005) Secondary chemotherapy for high-risk gestational trophoblastic neoplasia. Gynecol Oncol 97(2):618–623PubMedCrossRef

Madigan J, Freeman DJ, Menzies F et al (2010) Chemokine scavenger D6 is expressed by trophoblasts and aids the survival of mouse embryos transferred into allogeneic recipients. J Immunol 184(6):3202–3212PubMedCrossRef

Marth C, Berger P, Zwierzina H et al (1995) Modification of chorionic carcinoma cells by immunomodulators. Cytokines and chorionic carcinoma cells. Gynakol Geburtshilfliche Rundsch 35(Suppl 1):9–10PubMedCrossRef

Maskalenko NA, Zhigarev D, Campbell KS (2022) Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders. Nat Rev Drug Discov 21(8):559–577PubMedPubMedCentralCrossRef

Melsted WN, Matzen SH, Andersen MH et al (2018) The choriocarcinoma cell line JEG-3 upregulates regulatory T cell phenotypes and modulates pro-inflammatory cytokines through HLA-G. Cell Immunol 324:14–23PubMedCrossRef

Mirdamadi K, Kwok J, Nevo O et al (2021) Impact of Th-17 cytokines on the regulation of transporters in human placental explants. Pharmaceutics 13(6):881PubMedPubMedCentralCrossRef

Ngu SF, Ngan HYS (2021) Surgery including fertility-sparing treatment of GTD. Best Pract Res Clin Obstet Gynaecol 74:97–108PubMedCrossRef

Ni L, Dong C (2017) New B7 family checkpoints in human cancers. Mol Cancer Ther 16(7):1203–1211PubMedPubMedCentralCrossRef

Nishino K, Yamamoto E, Oda Y et al (2021) Short tandem repeat analysis to identify the causative pregnancy of high-risk gestational trophoblastic neoplasia: molar versus nonmolar pregnancy and its relation to the outcome. Placenta 112:28–35PubMedCrossRef

Onishi RM, Gaffen SL (2010) Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 129(3):311–321PubMedPubMedCentralCrossRef

Palma MB, Tronik-Le Roux D, Amín G et al (2021) HLA-G gene editing in tumor cell lines as a novel alternative in cancer immunotherapy. Sci Rep 11(1):22158PubMedPubMedCentralCrossRef

Persson G, Melsted WN, Nilsson LL et al (2017) HLA class Ib in pregnancy and pregnancy-related disorders. Immunogenetics 69(8–9):581–595PubMedCrossRef

Persson G, Bork JBS, Isgaard C et al (2020) Cytokine stimulation of the choriocarcinoma cell line JEG-3 leads to alterations in the HLA-G expression profile. Cell Immunol 352:104110PubMedCrossRef

Polnaszek B, Mullen M, Bligard K et al (2021) Term pregnancy after complete response of placental site trophoblastic tumor to immunotherapy. Obstet Gynecol 138(1):115–118PubMedCrossRef

Premyslova M, Chisaka H, Okamura K et al (2006) IL-1beta treatment does not co-ordinately up-regulate mPGES-1 and COX-2 mRNA expression, but results in higher degree of cellular and intracellular co-localization of their immunoreactive proteins in human placenta trophoblast cells. Placenta 27(6–7):576–586PubMedCrossRef

Rajashekhar G, Loganath A, Roy AC et al (2003) Co-expression of Fas (APO-1, CD95)/Fas ligand by BeWo and NJG choriocarcinoma cell lines. Gynecol Oncol 91(1):101–111PubMedCrossRef

Safarzadeh A, Alizadeh M, Beyranvand F et al (2021) Varied functions of immune checkpoints during cancer metastasis. Cancer Immunol Immunother 70(3):569–588PubMedCrossRef

Salman L, Bouchard-Fortier G, Covens A (2022) Immune checkpoint inhibitors for the treatment of gestational trophoblastic neoplasia: rationale, effectiveness, and future fertility. Curr Treat Options Oncol 23(7):1035–1043PubMedCrossRef

Savage P, Kelpanides I, Tuthill M et al (2015) Brain metastases in gestational trophoblast neoplasia: an update on incidence, management and outcome. Gynecol Oncol 137(1):73–76PubMedCrossRef

Seckl MJ, Sebire NJ, Berkowitz RS (2010) Gestational trophoblastic disease. Lancet 376(9742):717–729PubMedCrossRef

Shaarawy M, Darwish NA (1995) Serum cytokines in gestational trophoblastic diseases. Acta Oncol (stockholm, Sweden) 34(2):177–182CrossRef

Shapter AP, McLellan R (2001) Gestational trophoblastic disease. Obstet Gynecol Clin N Am 28(4):805–817CrossRef

Silva A, Monteiro KDN, Sun SY et al (2021) Gestational trophoblastic neoplasia: novelties and challenges. Placenta 116:38–42PubMedCrossRef

Sun SY, Melamed A, Goldstein DP et al (2015) Changing presentation of complete hydatidiform mole at the New England Trophoblastic Disease Center over the past three decades: does early diagnosis alter risk for gestational trophoblastic neoplasia? Gynecol Oncol 138(1):46–49PubMedCrossRef

Sundara YT, Jordanova ES, Hernowo BS et al (2012) Decidual infiltration of FoxP3⁺ regulatory T cells, CD3⁺ T cells, CD56⁺ decidual natural killer cells and Ki-67 trophoblast cells in hydatidiform mole compared to normal and ectopic pregnancies. Mol Med Rep 5(1):275–281PubMed

Tabarkiewicz J, Pogoda K, Karczmarczyk A et al (2015) The role of IL-17 and Th17 lymphocytes in autoimmune diseases. Arch Immunol Ther Exp 63(6):435–449CrossRef

Tameishi M, Kobori T, Tanaka C et al (2021) Contribution of ezrin on the cell surface plasma membrane localization of programmed cell death ligand-1 in human choriocarcinoma JEG-3 cells. Pharmaceuticals (basel) 14(10):963PubMedCrossRef

Terme M, Ullrich E, Aymeric L et al (2011) IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res 71(16):5393–5399PubMedCrossRef

Tripathi V, Kumar R, Dinda AK et al (2014) CXCL12-CXCR7 signaling activates ERK and Akt pathways in human choriocarcinoma cells. Cell Commun Adhes 21(4):221–228PubMedCrossRef

Tsonis O, Karpathiou G, Tsonis K et al (2020) Immune cells in normal pregnancy and gestational trophoblastic diseases. Placenta 101:90–96PubMedCrossRef

Veras E, Kurman RJ, Wang TL et al (2017) PD-L1 expression in human placentas and gestational trophoblastic diseases. Int J Gynecol Pathol 36(2):146–153PubMedPubMedCentralCrossRef

Viola A, Munari F, Sánchez-Rodríguez R et al (2019) The metabolic signature of macrophage responses. Front Immunol 10:1462PubMedPubMedCentralCrossRef

Waite JC, Skokos D (2012) Th17 response and inflammatory autoimmune diseases. Int J Inflamm 2012:819467CrossRef

Wang X, Fu S, Freedman RS et al (2006) Immunobiology of gestational trophoblastic diseases. Int J Gynecol Cancer 16(4):1500–1515PubMedCrossRef

Wang X, Cang W, Liu X et al (2023) Anti-PD-1 therapy plus chemotherapy versus anti-PD-1 therapy alone in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia: a multicenter, retrospective study. EClinicalMedicine 59:101974PubMedPubMedCentralCrossRef

Winter MC (2021) Treatment of low-risk gestational trophoblastic neoplasia. Best Pract Res Clin Obstet Gynaecol 74:67–80PubMedCrossRef

Wongweragiat S, Searle RF, Bulmer JN (1999) Decidual T lymphocyte activation in hydatidiform mole. J Clin Pathol 52(12):888–894PubMedPubMedCentralCrossRef

Yockey LJ, Iwasaki A (2018) Interferons and proinflammatory cytokines in pregnancy and fetal development. Immunity 49(3):397–412PubMedPubMedCentralCrossRef

You B, Bolze PA, Lotz JP et al (2020) Avelumab in patients with gestational trophoblastic tumors with resistance to single-agent chemotherapy: cohort A of the TROPHIMMUN phase II trial. J Clin Oncol 38(27):3129–3137PubMedPubMedCentralCrossRef

Zhao J, Lv WG, Feng FZ et al (2016) Placental site trophoblastic tumor: a review of 108 cases and their implications for prognosis and treatment. Gynecol Oncol 142(1):102–108PubMedCrossRef

Zhong T, Xie X, Zong T et al (2018) Lectin histochemical analysis of uterine natural killer cells in normal, hydatidiform molar and invasive molar pregnancy. Oncol Lett 16(5):6458–6464PubMedPubMedCentral

Zong L, Zhang M, Wang W et al (2019) PD-L1, B7–H3 and VISTA are highly expressed in gestational trophoblastic neoplasia. Histopathology 75(3):421–430PubMedCrossRef

Titel: Progress of immunotherapies in gestational trophoblastic neoplasms
verfasst von: Tong Wang
Wenxiu Guo
Xiaochen Ren
Fangfang Lang
Ying Ma
Chunping Qiu
Jie Jiang
Publikationsdatum: 18.08.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 16/2023
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-023-05010-8

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Progress of immunotherapies in gestational trophoblastic neoplasms

Abstract

Background

Purpose

Methods

Conclusion

Neu im Fachgebiet Onkologie

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Purpose

Methods

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 16/2023

Survival benefit and impact of adjuvant therapies following FOLFOX-HAIC-based conversion therapy with unresectable hepatocellular carcinoma: a retrospective cohort study

The promoting effects of GPR176 expression on proliferation, chemoresistance, lipogenesis and invasion of oesophageal cancer

Adherence to interdisciplinary tumor board recommendations as an expression of quality-assured patient care: results of a bicentric German analysis

Expression of four cancer-testis antigens in TNBC indicating potential universal immunotherapeutic targets

Predictive value of 18F-FDG PET/CT multi-metabolic parameters and tumor metabolic heterogeneity in the prognosis of gastric cancer

A novel postoperative nomogram and risk classification system for individualized estimation of survival among patients with parotid gland carcinoma after surgery

Neu im Fachgebiet Onkologie

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Update Onkologie